IVIG treatment and prognosis in Guillain-Barré syndrome - sprookjes - yvandenbroek - TriplyDB

IVIG treatment and prognosis in Guillain-Barré syndrome

IVIG treatment and prognosis in Guillain-Barré syndrome

http://www.wikidata.org/entity/Q22252627

about

sameAs

Zika Virus: Medical Countermeasure Development Challenges The role of genetics in IBS.Genetic polymorphism in pathogenesis of irritable bowel syndrome Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded tri Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.Traditional Chinese medicine Yisui Tongjing relieved neural severity in experimental autoimmune neuritis rat model.Guillain-Barre syndrome after coronary artery bypass surgery.Clinical importance of F-waves as a prognostic factor in Guillain-Barré syndrome in children.Guillain-Barré syndrome in pregnancy: A conservatively managed case Subcutaneous IgG in neurologic diseases.A Case of Acute Motor Axonal Neuropathy Mimicking Brain Death and Review of the Literature Differential diagnosis of amyotrophic lateral sclerosis from Guillain-Barré syndrome by quantitative determination of TDP-43 in cerebrospinal fluid.Successful treatment of Guillain-Barre syndrome by Ayurvedic treatment.Syringomyelia coexisting with guillain-barre syndrome.Peroral endoscopic myotomy for treatment of Guillain-Barre syndrome-associated achalasia: A rare case.Ethical, legal and societal considerations on Zika virus epidemics complications in scaling-up prevention and control strategies Silencing of miR155 promotes the production of inflammatory mediators in Guillain-Barré syndrome in vitro.Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis.Guillain-Barré syndrome risk among individuals infected with Zika virus: a multi-country assessment.Electrophysiological subtypes and prognosis of Guillain-Barré syndrome in Northeastern China Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients

P2860

Q24261184-0C1D6060-5BA5-42A3-8C7E-8ADD501C4CDE Q24600235-2E24CD90-5AF0-4EE1-B071-AFFAA59B2BA6 Q27008164-4EA228E5-03CA-4718-AF50-867CECAF6614 Q33750320-3E271C7F-1C9B-46DA-A091-886CBCE74EA9 Q35705601-D37F2259-F7F8-422F-A33B-58AC6C066735 Q36156604-24FB33D6-878D-415B-A0EE-D20D678F8A71 Q36161072-609AFA80-DE00-40B3-B67F-9D368250014F Q36345594-D5368694-1369-48A6-9633-528A4C03DB56 Q37121204-19D08D6C-6EF4-4348-92A1-561347C1660B Q37623255-D883A05C-5D23-4806-B405-415AFD012059 Q38171572-71517250-70C1-43BE-A16A-3A5FF48C6794 Q38839173-983DFDCF-7DBC-4785-99DF-AF7EC4CA0255 Q39091938-70883FD9-F9F2-498E-840B-451384938B8D Q40804681-2FAF016B-F479-4FB7-BA70-1AB5683362F1 Q42098126-9F7E509B-5C44-4785-AA33-62C2671A6FA1 Q42106267-4D0FA25D-FFBD-48C0-9728-A4814AFF981D Q42350952-5C368CEF-D208-460E-A1CD-C177926EA35F Q44322140-95072DFB-FD84-4C50-9A16-9594FC8276B7 Q53651047-2DDAFEFC-56DB-4F69-A651-90C2FF6AC148 Q54212362-0481070E-5CC9-4F94-8B3B-6F1D6F6D7A97 Q57630098-75F041C6-FCFC-409E-BDA5-3BAD9862523E Q58861212-CD5294D7-2188-474C-92C3-5E27548710B0

P2860

IVIG treatment and prognosis in Guillain-Barré syndrome

http://www.wikidata.org/entity/Q22252627

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

IVIG treatment and prognosis in Guillain-Barré syndrome

@ast

IVIG treatment and prognosis in Guillain-Barré syndrome

@en

IVIG treatment and prognosis in Guillain-Barré syndrome

@en-gb

IVIG treatment and prognosis in Guillain-Barré syndrome

@nl

type

label

IVIG treatment and prognosis in Guillain-Barré syndrome

@ast

IVIG treatment and prognosis in Guillain-Barré syndrome

@en

IVIG treatment and prognosis in Guillain-Barré syndrome

@en-gb

IVIG treatment and prognosis in Guillain-Barré syndrome

@nl

prefLabel

IVIG treatment and prognosis in Guillain-Barré syndrome

@ast

IVIG treatment and prognosis in Guillain-Barré syndrome

@en

IVIG treatment and prognosis in Guillain-Barré syndrome

@en-gb

IVIG treatment and prognosis in Guillain-Barré syndrome

@nl

P1433

Q22252627-1EAA1C8F-B299-4D72-A664-FC092DB75063

P1476

Q22252627-1075988F-3681-4AB7-B7C5-CF7F448F2E76

P2093

Q22252627-2881ACFE-C09A-4F7A-8610-31C1D3E2A095

Q22252627-AD992DD5-AC74-4C8A-AB4E-54C0480350E5

Q22252627-D947CED0-F703-42AC-B890-CD055407586B

Q22252627-F8F9FF6F-E659-4B81-9079-44F095D8C9CB

P2860

Q22252627-02DDE7D2-B0F1-4DE2-8698-444DE8373BA2

Q22252627-03B97AC3-67FE-4EEF-87DD-98177F9CF1FB

Q22252627-06D3E92C-083D-4550-A474-231FC23AD894

Q22252627-0E47C6B4-5DDB-434C-AC32-E41A7CD97867

Q22252627-0FD76DBC-9051-494A-AC14-B61EBDBE2DE6

Q22252627-1C4AFDCD-5A82-474C-B340-37E3985054C5

Q22252627-277343DA-0EDF-4C83-BB44-4B72C9D98E32

Q22252627-43B0811D-4A5D-4E86-8A84-A40822324B1F

Q22252627-74B549F4-69EA-44F9-ABCE-7C9DC3AA8F47

Q22252627-783F7D71-A894-4B50-A10E-F09F8FDFA0E9

P2888

Q22252627-ACC5BE36-498C-4798-AE8C-F2AE5A278030

P304

Q22252627-B2F5FCFB-DF40-4C0C-9C37-D377CCE59395

Q22252627-CA3181DF-3FC2-4839-9A75-B65077C85E8E

P31

Q22252627-9A722DAF-1C72-4F15-B17F-8EDE97F86865

Q22252627-CC93266A-A1C8-424F-B1D6-8F0E4C858090

P3181

Q22252627-DFBF2D25-AA6D-4E75-8E1F-FD966733A64C

P356

Q22252627-6A3D4098-C09A-44CC-928B-3D69B62C7B3B

P407

Q22252627-ACA62E69-ECE9-4BAE-A374-E38A30375D7E

P433

Q22252627-51E1E483-FA10-4435-90D4-9372C71133C6

Q22252627-8E0FD265-011E-483F-B315-271341D874E0

P478

Q22252627-37C775E8-F6C8-40E3-9F97-D2E60426DEA5

Q22252627-BFAA0A7B-DC83-4C1C-983E-888EC31E6971

P50

Q22252627-0DE4788F-0369-4FC8-868A-74F079A36610

Q22252627-5DD790DA-9924-4D71-AE09-3385807B7C8F

P577

Q22252627-168FB2EB-D875-4939-BC8D-4682410F7EB6

Q22252627-30653655-9019-4426-95BE-15E5B4FF0577

Q22252627-B7B489EE-2205-4D04-9660-6D992E23DD27

P5875

Q22252627-BBB7C93D-1C28-4FCD-AFBA-64B439C13D52

P6179

Q22252627-825F5D64-E26A-42DA-A476-55A63839242F

P698

Q22252627-5ADE44C0-1F04-4B2A-97C9-5CB76DE5A79C

P921

Q22252627-3130415E-9DFB-4CF6-9934-1688A6D12EFB

Q22252627-BAE02EDE-447F-4C29-9263-D17DF49C11D4

Q22252627-C081248C-770D-4C2A-97FF-FE22783B9B8D

P932

Q22252627-D4F692AC-15A0-46F3-84C4-7D59CC5619BC

P3181

P356

S10875-010-9407-4

P1433

Journal of Clinical Immunology

P1476

IVIG treatment and prognosis in Guillain-Barré syndrome

@en

P2093

Christa Walgaard

http://www.w3.org/2001/XMLSchema#string

Krista Kuitwaard

http://www.w3.org/2001/XMLSchema#string

Liselotte Ruts

http://www.w3.org/2001/XMLSchema#string

Rinske van Koningsveld

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotherapy for Guillain-Barre syndrome: a systematic review

Assessment of current diagnostic criteria for Guillain-Barré syndrome

The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study

Intravenous immunoglobulin for Guillain-Barré syndrome

Guillain-Barré syndrome

Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome

Plasma exchange for Guillain-Barré syndrome.

The immunobiology of Guillain-Barré syndromes.

A clinical prognostic scoring system for Guillain-Barré syndrome.

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

P2888

s10875-010-9407-4

P304

74-9

http://www.w3.org/2001/XMLSchema#string

S74-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2071818

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S10875-010-9407-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

S1

http://www.w3.org/2001/XMLSchema#string

P478

30 Suppl 1

http://www.w3.org/2001/XMLSchema#string

30

http://www.w3.org/2001/XMLSchema#string

P50

Pieter A van Doorn

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43161428

http://www.w3.org/2001/XMLSchema#string

P6179

1006653345

http://www.w3.org/2001/XMLSchema#string

P698

20396937

http://www.w3.org/2001/XMLSchema#string

P921

Guillain–Barré Syndrome

P932

2883091

http://www.w3.org/2001/XMLSchema#string